Najib Dally - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Najib Dally

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.

Nature Medicine|February 23, 2021

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.

Annals of Hematology|January 27, 2022

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.

Nature Medicine|February 23, 2021

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.

Annals of Hematology|January 27, 2022

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.

Pageof 4